A detailed history of Hsbc Holdings PLC transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 16,694 shares of BLUE stock, worth $6,009. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,694
Previous 20,751 19.55%
Holding current value
$6,009
Previous $20,000 60.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.47 - $1.35 $1,906 - $5,476
-4,057 Reduced 19.55%
16,694 $8,000
Q2 2024

Aug 12, 2024

BUY
$0.85 - $1.26 $187 - $277
220 Added 1.07%
20,751 $20,000
Q1 2024

May 15, 2024

BUY
$0.91 - $1.75 $18,683 - $35,929
20,531 New
20,531 $26,000
Q1 2023

May 15, 2023

BUY
$3.14 - $8.22 $53,964 - $141,268
17,186 New
17,186 $54,000
Q1 2021

May 14, 2021

SELL
$16.59 - $33.89 $178,359 - $364,351
-10,751 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$27.5 - $37.92 $59,345 - $81,831
2,158 Added 25.11%
10,751 $301,000
Q3 2020

Nov 12, 2020

BUY
$34.44 - $43.75 $117,440 - $149,187
3,410 Added 65.79%
8,593 $472,000
Q2 2020

Aug 14, 2020

BUY
$27.12 - $45.97 $16,841 - $28,547
621 Added 13.61%
5,183 $316,000
Q1 2020

May 15, 2020

SELL
$26.16 - $63.5 $218,122 - $529,463
-8,338 Reduced 64.64%
4,562 $210,000
Q4 2019

Feb 14, 2020

SELL
$46.96 - $61.67 $605,784 - $795,543
-12,900 Reduced 50.0%
12,900 $1.13 Million
Q3 2019

Nov 14, 2019

BUY
$59.47 - $93.1 $1.53 Million - $2.4 Million
25,800 New
25,800 $2.37 Million
Q3 2017

Nov 14, 2017

SELL
$57.74 - $91.42 $593,220 - $939,249
-10,274 Closed
0 $0
Q2 2017

Aug 14, 2017

BUY
N/A
10,274
10,274 $1.08 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $27.8M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.